Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LKM063
MIFTS: 70

Leukemia, Chronic Myeloid

Categories: Genetic diseases, Rare diseases, Blood diseases, Cancer diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia, Chronic Myeloid

About this section

MalaCards integrated aliases for Leukemia, Chronic Myeloid:

Name: Leukemia, Chronic Myeloid 57 53 75 13 38
Chronic Myelogenous Leukemia 12 76 53 25 59 75 29 6
Chronic Myeloid Leukemia 38 12 53 25 59 37 43 15
Cml 57 12 53 25 59 75
Chronic Granulocytic Leukemia 12 53 25 59
Leukemia, Chronic Myeloid, Atypical 75 29
Myeloid Leukemia, Chronic 12 73
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 73
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 75
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive 44
Leukemia, Chronic Myeloid, Somatic 57
Cml - Chronic Myelogenous Leukemia 12
Leukemia, Chronic Myelogenous 57
Chronic Myelocytic Leukemia 25
Leukemia, Myeloid, Chronic 40
Myeloid Leukemia Chronic 55
Acml 75
Cgl 25

Characteristics:

Orphanet epidemiological data:

59
chronic myeloid leukemia
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (United States); Age of onset: Adult;

OMIM:

57
Inheritance:
somatic mutation


HPO:

32
leukemia, chronic myeloid:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare haematological diseases


External Ids:

OMIM 57 608232
Disease Ontology 12 DOID:8552
ICD9CM 35 205.1
MeSH 44 D015464
NCIt 50 C3174
Orphanet 59 ORPHA521
UMLS via Orphanet 74 C0023473
ICD10 via Orphanet 34 C92.1
KEGG 37 H00004
Sources

Summaries for Leukemia, Chronic Myeloid

About this section
NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 521Disease definitionChronic myeloid leukaemia (CML) is the most common myeloproliferative disorder accounting for 15-20% of all leukaemia cases.EpidemiologyIts annual incidence has been estimated at between 1 and 1.5 cases per 100,000 and its prevalence at around 1 in 17,000.Clinical descriptionThe disease is typically triphasic with a chronic phase (CML-CP), accelerated phase (CML-AP) and blast phase (CML-BP). The majority of patients are diagnosed in the chronic phase and may be either asymptomatic (diagnosed through a routine white blood cell count) or present with fatigue, anaemia, weight loss, night sweats or splenomegaly.EtiologyCML is characterised by the presence of the Philadelphia chromosome, an abnormality resulting from a balanced translocation between chromosomes 9 and 22 (t(9;22)(q34;q11.2)). This translocation generates a BCR/ABL gene fusion encoding a constitutively active tyrosine kinase. CML does not appear to be an inherited disease and the factors leading to predisposition for the disorder remain largely unknown.Management and treatmentAlthough an allogeneic bone marrow transplant is viewed as the only curative treatment option, the prognosis for patients improved dramatically with the targeted development of imatinib mesylate. Imatinib mesylate is a competitive inhibitor of BCR/ABL tyrosine kinase activity and has held EU marketing authorisation as an Orphan drug for the treatment of CML since 2001.Visit the Orphanet disease page for more resources.

MalaCards based summary : Leukemia, Chronic Myeloid, also known as chronic myelogenous leukemia, is related to atypical chronic myeloid leukemia and philadelphia-negative chronic myeloid leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia, Chronic Myeloid is BCR (BCR, RhoGEF And GTPase Activating Protein), and among its related pathways/superpathways are Chronic myeloid leukemia and Endometrial cancer. The drugs Bosulif and Busulfex have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are myeloproliferative disorder and splenomegaly

Disease Ontology : 12 A myeloid leukemia that is characterized by over production of white blood cells.

Genetics Home Reference : 25 Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow produces red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In chronic myeloid leukemia, the bone marrow produces too many white blood cells. Initially, these cells function relatively normally. However, as the condition progresses, immature white blood cells called myeloblasts (or blasts) accumulate in the blood and bone marrow. The overgrowth of myeloblasts impairs development of other blood cells, leading to a shortage of red blood cells (anemia) and platelets.

MedlinePlus : 43 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic myeloid leukemia (CML), there are too many granulocytes, a type of white blood cell. Most people with CML have a gene mutation (change) called the Philadelphia chromosome. Sometimes CML does not cause any symptoms. If you have symptoms, they may include: Fatigue Weight loss Night sweats Fever Pain or a feeling of fullness below the ribs on the left side Tests that examine the blood and bone marrow diagnose CML. Treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 75 Leukemia, chronic myeloid: A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts. Leukemia, chronic myeloid, atypical: A myeloproliferative disorder that shares clinical and laboratory features with chronic myeloid leukemia but lacks the pathognomonic Philadelphia chromosome and the corresponding BCR/ABL1 fusion transcript. Features include myeloid predominance in the bone marrow, myeloid proliferation and low leukocyte alkaline phosphatase value, splenomegaly, hepatomegaly, elevated white blood cell count. Enlarged spleen may also be associated with a hypermetabolic state, fever, weight loss, and chronic fatigue. The enlarged liver may contribute to the patient's weight loss.

Wikipedia : 76 Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white... more...

Description from OMIM: 608232
Sources

Related Diseases for Leukemia, Chronic Myeloid

About this section

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Acute Myeloid Leukemia with T(9;11)(p22;q23) Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Chronic Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Related Disease Score Top Affiliating Genes
1 atypical chronic myeloid leukemia 35.9 ABL1 CSF3R JAK2 RUNX1 SETBP1
2 philadelphia-negative chronic myeloid leukemia 35.4 ABL1 BCR
3 myeloproliferative neoplasm 34.2 ABL1 BCR H19 JAK2 KIT
4 leukemia 34.0 ABL1 BCR CSF3R HOTAIR JAK2 KIT
5 myeloid leukemia 32.5 ABL1 BCR CSF3R JAK2 KIT NRAS
6 myelodysplastic syndrome 31.3 ABL1 CSF3R JAK2 KIT MEG3 MIR10A
7 acute promyelocytic leukemia 31.2 CSF3R MIR223 NRAS RUNX1
8 acute leukemia 30.2 JAK2 KIT RUNX1
9 myelocytic leukemia-like syndrome, familial, chronic 11.9
10 chromosome 22q11.2 deletion syndrome, distal 11.4 BCR CRKL
11 myelodysplastic myeloproliferative cancer 11.4 CSF3R JAK2 NRAS SETBP1
12 neutrophilia, hereditary 11.4 CSF3R JAK2 MIR223
13 functionless pituitary adenoma 11.3 HOTAIR MEG3
14 leukemia, acute lymphoblastic 11.3 ABL1 BCR MIR203A MIR223 RUNX1
15 core binding factor acute myeloid leukemia 11.3 JAK2 KIT NRAS RUNX1
16 chronic myelomonocytic leukemia 11.3 JAK2 KIT RUNX1 SETBP1
17 pituitary adenoma 11.3 H19 HOTAIR MEG3 MIR223
18 gastric cardia adenocarcinoma 11.3 H19 HOTAIR MEG3
19 pancreatic ductal adenocarcinoma 11.3 H19 HOTAIR MIR203A MIR223 UCA1
20 kidney cancer 11.3 H19 HOTAIR MEG3 MIR20A
21 ovarian epithelial cancer 11.3 H19 HOTAIR HULC MEG3
22 8p11 myeloproliferative syndrome 11.3 BCR KIT RUNX1
23 essential thrombocythemia 11.3 ABL1 BCR JAK2 MIR223
24 lymphoblastic leukemia 11.3 ABL1 BCR HOTAIR JAK2 RUNX1
25 polycythemia vera 11.3 ABL1 H19 JAK2 KIT
26 hematologic cancer 11.3 ABL1 BCR CSF3R JAK2 KIT RUNX1
27 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.3 KIT RUNX1
28 juvenile myelomonocytic leukemia 11.3 JAK2 NRAS RUNX1 SETBP1
29 leukemia, acute lymphoblastic 3 11.3 ABL1 BCR RUNX1
30 osteogenic sarcoma 11.3 H19 HOTAIR HULC MEG3 UCA1
31 gallbladder cancer 11.3 H19 HOTAIR MEG3 UCA1
32 bone marrow cancer 11.3 ABL1 BCR CSF3R IRF8 JAK2 KIT
33 myeloma, multiple 11.3 H19 HOTAIR MEG3 NRAS UCA1
34 endometriosis 11.3 H19 MIR20A MIR223
35 thyroid cancer, nonmedullary, 1 11.3 H19 HOTAIR HULC MEG3
36 oral squamous cell carcinoma 11.2 H19 HOTAIR MEG3 MIR10A MIR203A MIR223
37 adamantinoma of long bones 11.2 H19 HOTAIR HULC MEG3 UCA1
38 esophagus squamous cell carcinoma 11.2 HOTAIR MEG3
39 myelofibrosis 11.2 JAK2 KIT MEG3 MIR223
40 glioma 11.2 H19 HOTAIR HULC MEG3 MIR20A UCA1
41 nasopharyngeal carcinoma 11.2 H19 HOTAIR HULC MEG3 NRAS
42 cervical cancer 11.2 H19 HOTAIR HULC MEG3 UCA1
43 severe congenital neutropenia 11.2 CSF3R JAK2 RUNX1
44 esophageal cancer 11.2 H19 HOTAIR HULC MEG3 MIR203A MIR223
45 gastrointestinal system cancer 11.2 H19 HOTAIR KIT
46 bladder cancer 11.2 H19 HOTAIR HULC MEG3 MIR10A MIR203A
47 gastric cancer 11.2 H19 HOTAIR HULC MEG3 MIR203A MIR20A
48 melanoma 11.2 H19 HOTAIR MEG3 NRAS UCA1
49 lung cancer susceptibility 3 11.2 H19 HOTAIR MEG3 NRAS
50 pancreatic cancer 11.2 H19 HOTAIR HULC MEG3 MIR10A MIR203A

Comorbidity relations with Leukemia, Chronic Myeloid via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Leukemia, Chronic Myeloid:



Diseases related to Leukemia, Chronic Myeloid
Sources

Symptoms & Phenotypes for Leukemia, Chronic Myeloid

About this section

Symptoms via clinical synopsis from OMIM:

57
Hematology:
chronic myelogenous leukemia
ph-positive acute lymphoblastic leukemia

Laboratory Abnormalities:
low leukocyte alkaline phosphatase activity
presence of the philadelphia chromosome (translocation of 9q34 and 22q11) in greater than 95% of patients
two alternative chimeric oncogene products called p210(bcr-abl) and p185(bcr-abl)
detection by rt-pcr, southern blot analysis, and fish for primary diagnosis and follow up for residual disease


Clinical features from OMIM:

608232

Human phenotypes related to Leukemia, Chronic Myeloid:

59 32 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myeloproliferative disorder 59 32 obligate (100%) Obligate (100%) HP:0005547
2 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
3 thrombocytopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001873
4 thrombocytosis 59 32 frequent (33%) Frequent (79-30%) HP:0001894
5 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
6 leukocytosis 59 32 frequent (33%) Frequent (79-30%) HP:0001974
7 poor appetite 59 32 frequent (33%) Frequent (79-30%) HP:0004396
8 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
9 abnormality of blood and blood-forming tissues 59 Frequent (79-30%)
10 abnormality of granulocytes 59 Frequent (79-30%)
11 abnormality of basophils 59 Frequent (79-30%)
12 ph-positive acute lymphoblastic leukemia 32 HP:0004848
13 reduced leukocyte alkaline phosphatase 32 HP:0004852
14 chronic myelogenous leukemia 32 HP:0005506
15 abnormal basophil morphology 32 frequent (33%) HP:0001912

UMLS symptoms related to Leukemia, Chronic Myeloid:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Leukemia, Chronic Myeloid:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.56 ABL1 BCR CRKL IRF8 JAK2 KIT
2 neoplasm MP:0002006 9.1 CRKL IRF8 JAK2 KIT NRAS RUNX1
Sources

Drugs & Therapeutics for Leukemia, Chronic Myeloid

About this section

FDA approved drugs:

(show all 7)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
2
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
3
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
4
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
5
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
6
Synribo 18 49 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
7
Tasigna 18 49 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007

Drugs for Leukemia, Chronic Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 482)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
3
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
4
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
5
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
6 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
7
Lactitol Investigational Phase 4,Phase 2,Phase 3,Phase 1 585-86-4 3871
8 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 220127-57-1 123596
9 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
16 interferons Phase 4,Phase 3,Phase 2,Phase 1
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Tin Fluorides Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 tyrosine Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
25
Hydroxyurea Approved Phase 3,Phase 2,Phase 1,Not Applicable 127-07-1 3657
26
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
27
Idarubicin Approved Phase 3,Phase 2,Phase 1 58957-92-9 42890
28
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
29
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
30
Iron Approved Phase 2, Phase 3,Phase 1,Not Applicable 7439-89-6 23925
31
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
32
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
33
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
34
Ofloxacin Approved Phase 3 82419-36-1 4583
35
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
36
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
37
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
38
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
39
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
40
Peginterferon alfa-2b Approved Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
41
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
42
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
43
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
44
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
45
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
46
Vidarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
47
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
48
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
49
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
50
Ponatinib Approved, Investigational Phase 3,Phase 2,Phase 1 943319-70-8 24826799

Interventional clinical trials:

(show top 50) (show all 1162)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
2 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
3 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
4 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
5 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
6 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
7 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
8 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
9 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
10 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
11 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
12 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
13 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4 Nilotinib
14 Efficacy and Safety of Nilotinib in CML-CP Completed NCT03332511 Phase 4 Nilotinib
15 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
16 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
17 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4 nilotinib
18 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
19 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Recruiting NCT03216070 Phase 4 Dasatinib 50 MG
20 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
21 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4 Nilotinib
22 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib
23 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients Active, not recruiting NCT01578213 Phase 4 Imatinib mesylate
24 Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Not yet recruiting NCT02389920 Phase 4 Nilotinib
25 Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib Terminated NCT00461929 Phase 4
26 A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients Terminated NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
27 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
28 Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy Terminated NCT02086487 Phase 4 Nilotinib 300 mg.
29 Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. Withdrawn NCT01605981 Phase 4 AMN107
30 Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia Unknown status NCT00002869 Phase 3 cytarabine;hydroxyurea
31 Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00002771 Phase 3 busulfan;cytarabine;hydroxyurea;idarubicin
32 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
33 Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase Unknown status NCT00327262 Phase 3 Imatinib
34 Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion Unknown status NCT00966810 Phase 2, Phase 3
35 Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib Unknown status NCT01400074 Phase 3 Nilotinib, Imatinib
36 Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy Unknown status NCT00297570 Phase 3 Pegylated Interferon and Imatinib
37 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
38 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
39 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
40 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
41 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
42 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
43 Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Completed NCT01254188 Phase 3 Nilotinib
44 Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase Completed NCT00451035 Phase 2, Phase 3 LBH589
45 Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Completed NCT00333840 Phase 3 imatinib mesilate;interferon-alpha (INF-a);cytarabine (ARA-C)
46 Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions Completed NCT02103322 Phase 2, Phase 3 Imatinib Mesylate Tablets, 400 mg;Imatinib Mesylate Tablets, 400 mg
47 Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) Completed NCT00237120 Phase 3 Imatinib
48 Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML Completed NCT00123474 Phase 3 dasatinib;dasatinib;dasatinib;dasatinib
49 STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia Completed NCT00006343 Phase 3 cytarabine;imatinib mesylate
50 A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Completed NCT00481247 Phase 3 Dasatinib;Imatinib

Search NIH Clinical Center for Leukemia, Chronic Myeloid

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Myeloid cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Chronic Myeloid:
Hemacord
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx
Embryonic/Adult Cultured Cells Related to Leukemia, Chronic Myeloid:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Cochrane evidence based reviews: leukemia, myelogenous, chronic, bcr-abl positive

Sources

Genetic Tests for Leukemia, Chronic Myeloid

About this section

Genetic tests related to Leukemia, Chronic Myeloid:

# Genetic test Affiliating Genes
1 Chronic Myelogenous Leukemia 29 BCR
2 Leukemia, Chronic Myeloid, Atypical 29
Sources

Anatomical Context for Leukemia, Chronic Myeloid

About this section

MalaCards organs/tissues related to Leukemia, Chronic Myeloid:

41
Myeloid, Bone, Bone Marrow, T Cells, Spleen, Testes, Neutrophil
Sources

Publications for Leukemia, Chronic Myeloid

About this section

Articles related to Leukemia, Chronic Myeloid:

(show top 50) (show all 902)
# Title Authors Year
1
Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. ( 29941400 )
2018
2
Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US. ( 29095654 )
2018
3
A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis. ( 29187020 )
2018
4
Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy. ( 29447062 )
2018
5
The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities. ( 29386476 )
2018
6
miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1. ( 28260112 )
2017
7
Atypical Presentation of Chronic Myelogenous Leukemia. ( 28656128 )
2017
8
DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells. ( 28376405 )
2017
9
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. ( 28435223 )
2017
10
miRNA-301a induces apoptosis of chronic myelogenous leukemia cells by directly targeting TIMP2/ERK1/2 and AKT pathways. ( 28035415 )
2017
11
Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. ( 29021516 )
2017
12
Tuberostemonine reverses multidrug resistance in chronic myelogenous leukemia cells K562/ADR. ( 28529625 )
2017
13
Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing I^-Catenin. ( 27852702 )
2017
14
Indole-3-carbinol induces apoptosis of chronic myelogenous leukemia cells through suppression of STAT5 and Akt signaling pathways. ( 28631564 )
2017
15
Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia. ( 28086219 )
2017
16
Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients. ( 28387753 )
2017
17
Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia. ( 28978042 )
2017
18
With no interaction, knockdown of Apollon and MDR1 reverse the multidrug resistance of human chronic myelogenous leukemia K562/ADM cells. ( 28358418 )
2017
19
Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia. ( 28103766 )
2017
20
Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/I^-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. ( 27492973 )
2017
21
Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. ( 26956626 )
2016
22
Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib. ( 27028020 )
2016
23
RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia. ( 26967392 )
2016
24
Gastric Antral Vascular Ectasia during the Treatment of Chronic Myelogenous Leukemia with Imatinib Mesylate. ( 26726089 )
2016
25
Heralding Extramedullary Blast Crisis: Horner's Syndrome with Brachial Plexopathy in a Patient with Chronic Myelogenous Leukemia. ( 28096817 )
2016
26
Coexistent chronic myelogenous leukemia with squamous cell carcinoma of the larynx associated with NOD2/CARD15 mutation in a young adult. ( 27304445 )
2016
27
Chronic myelogenous leukemia with acquired t(11;14)(q13;q32) CCND1-IGH: A case report and literature review. ( 27810077 )
2016
28
Chronic myelogenous leukemia evolving after treatment of multiple myeloma. ( 28092869 )
2016
29
Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. ( 27103978 )
2016
30
Curcumin modulates chronic myelogenous leukemia exosomes composition and affects angiogenic phenotype via exosomal miR-21. ( 27050372 )
2016
31
High-performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in Human Plasma from Patients with Chronic Myelogenous Leukemia, and Comparison with Liquid Chromatography-Tandem Mass Spectrometry. ( 27194024 )
2016
32
Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. ( 26984633 )
2016
33
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. ( 27643437 )
2016
34
Deciphering the cross-talking of human competitive endogenous RNAs in K562 chronic myelogenous leukemia cell line. ( 27730241 )
2016
35
Blast phase transformation of chronic myelogenous leukemia presenting with central nervous system manifestation. ( 26889299 )
2016
36
Co-expression Pattern Analysis of miR-17-92 Target Genes in Chronic Myelogenous Leukemia. ( 27708666 )
2016
37
Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. ( 27152845 )
2016
38
Myeloid sarcoma presenting as a colon polyp and harbinger of chronic myelogenous leukemia. ( 26989468 )
2016
39
Armillaridin induces autophagy-associated cell death in human chronic myelogenous leukemia K562 cells. ( 27592257 )
2016
40
Chronic Localized Fibrosing Leukocytoclastic Vasculitis Associated With Lymphedema, Intralymphatic and Intravascular Lymphocytosis, and Chronic Myelogenous Leukemia: A Case Report of Unilateral Erythema Elevatum Diutinum. ( 27930381 )
2016
41
Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature. ( 28253493 )
2016
42
Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. ( 27630126 )
2016
43
A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting with Severe Thrombocytosis without Leukocytosis. ( 27454200 )
2016
44
Novel structural co-expression analysis linking the NPM1-associated ribosomal biogenesis network to chronic myelogenous leukemia. ( 26205693 )
2015
45
Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis. ( 25556390 )
2015
46
The -137G/C Polymorphism in Interleukin-18 Gene Promoter Contributes to Chronic Lymphocytic and Chronic Myelogenous Leukemia Risk in Turkish Patients. ( 26376814 )
2015
47
Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. ( 26117541 )
2015
48
Chronic myelogenous leukemia in eastern Pennsylvania: an assessment of registry reporting. ( 25961786 )
2015
49
Nilotinib rapidly reverses breakpoint cluster region-Abelson oncogene fusion gene and M244V mutations in a patient with chronic myelogenous leukemia: A case report. ( 26622510 )
2015
50
Methylenetetrahydrofolate reductase gene polymorphism and risk of chronic myelogenous leukemia: a meta-analysis. ( 26854451 )
2015
Sources

Variations for Leukemia, Chronic Myeloid

About this section

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Chronic Myeloid:

75
# Symbol AA change Variation ID SNP ID
1 SETBP1 p.Asp868Asn VAR_063807 rs267607042
2 SETBP1 p.Gly870Ser VAR_063809 rs267607040
3 SETBP1 p.Ile871Thr VAR_063810 rs267607038
4 SETBP1 p.Glu858Lys VAR_069849

ClinVar genetic disease variations for Leukemia, Chronic Myeloid:

6
(show top 50) (show all 66)
# Gene Variation Type Significance SNP ID Assembly Location
1 SETBP1 NM_015559.2(SETBP1): c.2608G> A (p.Gly870Ser) single nucleotide variant Pathogenic rs267607040 GRCh37 Chromosome 18, 42531913: 42531913
2 SETBP1 NM_015559.2(SETBP1): c.2608G> A (p.Gly870Ser) single nucleotide variant Pathogenic rs267607040 GRCh38 Chromosome 18, 44951948: 44951948
3 ABL1 NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913459 GRCh37 Chromosome 9, 133748283: 133748283
4 ABL1 NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913459 GRCh38 Chromosome 9, 130872896: 130872896
5 ABL1 NM_007313.2(ABL1): c.763G> A (p.Glu255Lys) single nucleotide variant Pathogenic/Likely pathogenic rs387906517 GRCh37 Chromosome 9, 133738306: 133738306
6 ABL1 NM_007313.2(ABL1): c.763G> A (p.Glu255Lys) single nucleotide variant Pathogenic/Likely pathogenic rs387906517 GRCh38 Chromosome 9, 130862919: 130862919
7 ABL1 NM_007313.2(ABL1): c.814T> C (p.Tyr272His) single nucleotide variant Pathogenic/Likely pathogenic rs121913461 GRCh37 Chromosome 9, 133738357: 133738357
8 ABL1 NM_007313.2(ABL1): c.814T> C (p.Tyr272His) single nucleotide variant Pathogenic/Likely pathogenic rs121913461 GRCh38 Chromosome 9, 130862970: 130862970
9 ABL1 NM_007313.2(ABL1): c.1109T> C (p.Met370Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121913457 GRCh37 Chromosome 9, 133748391: 133748391
10 ABL1 NM_007313.2(ABL1): c.1109T> C (p.Met370Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121913457 GRCh38 Chromosome 9, 130873004: 130873004
11 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
12 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh38 Chromosome 9, 5073770: 5073770
13 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
14 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 GRCh38 Chromosome 1, 114716127: 114716127
15 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh37 Chromosome 7, 140453193: 140453193
16 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh38 Chromosome 7, 140753393: 140753393
17 CSF3R NM_156039.3(CSF3R): c.1853C> T (p.Thr618Ile) single nucleotide variant Pathogenic/Likely pathogenic rs796065343 GRCh37 Chromosome 1, 36933434: 36933434
18 CSF3R NM_156039.3(CSF3R): c.1853C> T (p.Thr618Ile) single nucleotide variant Pathogenic/Likely pathogenic rs796065343 GRCh38 Chromosome 1, 36467833: 36467833
19 ABL1 NM_005157.5(ABL1): c.730A> G (p.Met244Val) single nucleotide variant Likely pathogenic rs121913456 GRCh37 Chromosome 9, 133738330: 133738330
20 ABL1 NM_005157.5(ABL1): c.730A> G (p.Met244Val) single nucleotide variant Likely pathogenic rs121913456 GRCh38 Chromosome 9, 130862943: 130862943
21 ABL1 NM_005157.5(ABL1): c.742C> G (p.Leu248Val) single nucleotide variant Likely pathogenic rs121913455 GRCh37 Chromosome 9, 133738342: 133738342
22 ABL1 NM_005157.5(ABL1): c.742C> G (p.Leu248Val) single nucleotide variant Likely pathogenic rs121913455 GRCh38 Chromosome 9, 130862955: 130862955
23 ABL1 NM_005157.5(ABL1): c.749G> A (p.Gly250Glu) single nucleotide variant Likely pathogenic rs121913453 GRCh37 Chromosome 9, 133738349: 133738349
24 ABL1 NM_005157.5(ABL1): c.749G> A (p.Gly250Glu) single nucleotide variant Likely pathogenic rs121913453 GRCh38 Chromosome 9, 130862962: 130862962
25 ABL1 NM_005157.5(ABL1): c.756G> C (p.Gln252His) single nucleotide variant Likely pathogenic rs121913458 GRCh37 Chromosome 9, 133738356: 133738356
26 ABL1 NM_005157.5(ABL1): c.756G> C (p.Gln252His) single nucleotide variant Likely pathogenic rs121913458 GRCh38 Chromosome 9, 130862969: 130862969
27 ABL1 NM_007313.2(ABL1): c.813G> T (p.Gln271His) single nucleotide variant Likely pathogenic rs121913458 GRCh37 Chromosome 9, 133738356: 133738356
28 ABL1 NM_007313.2(ABL1): c.813G> T (p.Gln271His) single nucleotide variant Likely pathogenic rs121913458 GRCh38 Chromosome 9, 130862969: 130862969
29 ABL1 NM_005157.5(ABL1): c.758A> T (p.Tyr253Phe) single nucleotide variant Likely pathogenic rs121913460 GRCh37 Chromosome 9, 133738358: 133738358
30 ABL1 NM_005157.5(ABL1): c.758A> T (p.Tyr253Phe) single nucleotide variant Likely pathogenic rs121913460 GRCh38 Chromosome 9, 130862971: 130862971
31 ABL1 NM_007313.2(ABL1): c.820G> A (p.Glu274Lys) single nucleotide variant Likely pathogenic rs121913448 GRCh37 Chromosome 9, 133738363: 133738363
32 ABL1 NM_007313.2(ABL1): c.820G> A (p.Glu274Lys) single nucleotide variant Likely pathogenic rs121913448 GRCh38 Chromosome 9, 130862976: 130862976
33 ABL1 NM_005157.5(ABL1): c.764A> T (p.Glu255Val) single nucleotide variant Likely pathogenic rs121913449 GRCh37 Chromosome 9, 133738364: 133738364
34 ABL1 NM_005157.5(ABL1): c.764A> T (p.Glu255Val) single nucleotide variant Likely pathogenic rs121913449 GRCh38 Chromosome 9, 130862977: 130862977
35 ABL1 NM_005157.5(ABL1): c.847T> G (p.Phe283Val) single nucleotide variant Likely pathogenic rs1057519758 GRCh37 Chromosome 9, 133747540: 133747540
36 ABL1 NM_005157.5(ABL1): c.847T> G (p.Phe283Val) single nucleotide variant Likely pathogenic rs1057519758 GRCh38 Chromosome 9, 130872153: 130872153
37 ABL1 NM_005157.5(ABL1): c.951C> A (p.Phe317Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh38 Chromosome 9, 130872903: 130872903
38 ABL1 NM_005157.5(ABL1): c.951C> A (p.Phe317Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh37 Chromosome 9, 133748290: 133748290
39 ABL1 NM_007313.2(ABL1): c.1008C> G (p.Phe336Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh37 Chromosome 9, 133748290: 133748290
40 ABL1 NM_007313.2(ABL1): c.1008C> G (p.Phe336Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh38 Chromosome 9, 130872903: 130872903
41 ABL1 NM_005157.5(ABL1): c.1064A> G (p.Glu355Gly) single nucleotide variant Likely pathogenic rs121913450 GRCh37 Chromosome 9, 133748403: 133748403
42 ABL1 NM_005157.5(ABL1): c.1064A> G (p.Glu355Gly) single nucleotide variant Likely pathogenic rs121913450 GRCh38 Chromosome 9, 130873016: 130873016
43 ABL1 NM_005157.5(ABL1): c.1075T> G (p.Phe359Val) single nucleotide variant Likely pathogenic rs121913452 GRCh37 Chromosome 9, 133748414: 133748414
44 ABL1 NM_005157.5(ABL1): c.1075T> G (p.Phe359Val) single nucleotide variant Likely pathogenic rs121913452 GRCh38 Chromosome 9, 130873027: 130873027
45 ABL1 NM_005157.5(ABL1): c.1187A> G (p.His396Arg) single nucleotide variant Likely pathogenic rs121913454 GRCh37 Chromosome 9, 133750356: 133750356
46 ABL1 NM_005157.5(ABL1): c.1187A> G (p.His396Arg) single nucleotide variant Likely pathogenic rs121913454 GRCh38 Chromosome 9, 130874969: 130874969
47 ABL1 NM_007313.2(ABL1): c.952G> C (p.Val318Leu) single nucleotide variant Likely pathogenic rs1057519771 GRCh37 Chromosome 9, 133747588: 133747588
48 ABL1 NM_007313.2(ABL1): c.952G> C (p.Val318Leu) single nucleotide variant Likely pathogenic rs1057519771 GRCh38 Chromosome 9, 130872201: 130872201
49 ABL1 NM_005157.5(ABL1): c.943A> G (p.Thr315Ala) single nucleotide variant Likely pathogenic rs1057519772 GRCh37 Chromosome 9, 133748282: 133748282
50 ABL1 NM_005157.5(ABL1): c.943A> G (p.Thr315Ala) single nucleotide variant Likely pathogenic rs1057519772 GRCh38 Chromosome 9, 130872895: 130872895

Copy number variations for Leukemia, Chronic Myeloid from CNVD:

7 (show all 45)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 37133 1 858000 52858291 Copy numbercopy numb erLOH Chronic myeloid leukemia
2 44672 10 61218526 61336824 Translate D10S170 Chronic myelogenous leukemia
3 56890 11 61840484 62345935 Loss Chronic myeloid leukemia
4 59436 11 75208816 75845444 Loss Chronic myeloid leukemia
5 78023 13 48911492 50087172 Loss Chronic myeloid leukemia
6 83260 14 19767470 106339477 Gain Chronic myeloid leukemia
7 84230 14 24600000 33300000 Deletion Chronic myeloid leukemia
8 99762 16 28519207 31440323 Loss Chronic myeloid leukemia
9 138867 2 172217486 173146666 Loss Chronic myeloid leukemia
10 143230 2 234301355 238853232 Loss Chronic myeloid leukemia
11 162523 22 21962191 22180167 Loss Chronic myeloid leukemia
12 162524 22 21962191 22410163 Loss Chronic myeloid leukemia
13 162525 22 21962191 23748456 Loss Chronic myeloid leukemia
14 162526 22 21963005 23840758 Loss Chronic myeloid leukemia
15 162527 22 21965685 22103948 Loss Chronic myeloid leukemia
16 162528 22 21965685 22211587 Loss Chronic myeloid leukemia
17 162529 22 21965685 22575018 Loss Chronic myeloid leukemia
18 162530 22 21965685 23038955 Loss Chronic myeloid leukemia
19 162531 22 21965685 23404027 Loss Chronic myeloid leukemia
20 162532 22 21965685 23779268 Loss Chronic myeloid leukemia
21 162533 22 21969649 23264408 Loss Chronic myeloid leukemia
22 162539 22 21996232 23317147 Loss Chronic myeloid leukemia
23 162540 22 22020300 22659711 Loss Chronic myeloid leukemia
24 162567 22 22184646 22476629 Loss Chronic myeloid leukemia
25 162599 22 22374488 22513875 Loss Chronic myeloid leukemia
26 162992 22 23595985 23627388 Copy number Chronic myeloid leukemia
27 227187 7 65425674 65447246 Copy number GUSB Chronic myeloid leukemia
28 229935 7 97199324 142723486 Loss Chronic myeloid leukemia
29 231976 8 109706119 120929916 Loss Chronic myeloid leukemia
30 239048 8 3687491 5908007 Loss Chronic myeloid leukemia
31 247260 9 129645960 132672275 Loss Chronic myeloid leukemia
32 247319 9 130014643 132618574 Loss Chronic myeloid leukemia
33 247584 9 130432414 131425779 Loss Chronic myeloid leukemia
34 247725 9 130855419 132584828 Loss Chronic myeloid leukemia
35 247730 9 130896183 132618574 Loss Chronic myeloid leukemia
36 247834 9 131532978 132607062 Loss Chronic myeloid leukemia
37 247856 9 131641050 132590178 Loss Chronic myeloid leukemia
38 247886 9 131997035 132590178 Loss Chronic myeloid leukemia
39 247924 9 132362204 132593161 Loss Chronic myeloid leukemia
40 247932 9 132430323 132610819 Loss Chronic myeloid leukemia
41 248025 9 132985174 134219212 Loss Chronic myeloid leukemia
42 248051 9 133107127 133390056 Loss Chronic myeloid leukemia
43 248180 9 133589267 133763060 Copy number ABL1 Chronic myeloid leukemia
44 250432 9 212399 32604310 Loss Chronic myeloid leukemia
45 251914 9 3330 20811568 Copy numbercopy numb erLOH Chronic myeloid leukemia
Sources

Expression for Leukemia, Chronic Myeloid

About this section
Search GEO for disease gene expression data for Leukemia, Chronic Myeloid.
Sources

Pathways for Leukemia, Chronic Myeloid

About this section

Pathways related to Leukemia, Chronic Myeloid according to KEGG:

37
# Name Kegg Source Accession
1 Chronic myeloid leukemia hsa05220

Pathways related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.54 ABL1 BCR CRKL KIT NRAS RUNX1
2
Pathways in cancer 37
12.28 ABL1 BCR CRKL CSF3R JAK2 KIT
3
NF-kappaB Signaling 4
12.27 IRF8 JAK2 KIT RUNX1
4
Tyrosine Kinases / Adaptors 4
11.72 ABL1 BCR CRKL JAK2 KIT
5
MicroRNAs in cancer 37
11.64 ABL1 CRKL MIR10A MIR203A MIR20A MIR223
6
Jak-Stat Signaling Pathway 67
11.61 ABL1 CSF3R JAK2 NRAS
7
Gefitinib Pathway, Pharmacokinetics 61
Show member pathways
 11.37 ABL1 BCR KIT
8
Transcription_Transcription factor Tubby signaling pathways 22
11.02 ABL1 JAK2 NRAS
9
LncRNA-mediated mechanisms of therapeutic resistance 1
10.51 HOTAIR MEG3 UCA1
Sources

GO Terms for Leukemia, Chronic Myeloid

About this section

Biological processes related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.67 CRKL CSF3R JAK2 KIT
2 protein autophosphorylation GO:0046777 9.46 ABL1 BCR JAK2 KIT
3 negative regulation of cell-cell adhesion GO:0022408 9.32 ABL1 JAK2
4 regulation of myeloid cell differentiation GO:0045637 9.26 CSF3R RUNX1
5 peptidyl-tyrosine phosphorylation GO:0018108 9.26 ABL1 BCR JAK2 KIT
6 platelet-derived growth factor receptor signaling pathway GO:0048008 8.8 ABL1 BCR JAK2

Molecular functions related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 8.92 ABL1 BCR JAK2 KIT
Sources

Sources for Leukemia, Chronic Myeloid

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....